News from relmada therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 24, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Mar 17, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Reports Positive Phase 1 Results for NMDA Receptor Antagonist d-Methadone

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Mar 12, 2015, 09:51 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at Future Leaders in the Biotech Industry Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced...

Mar 05, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Mar 03, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at ROTH Capital Partners 27th Annual Growth Stock Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today...

Feb 24, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced...

Feb 09, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Feb 04, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Selects MepiGel Formulations to Advance Into Clinical Studies

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Jan 16, 2015, 08:30 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Jan 13, 2015, 08:00 ET
Relmada Therapeutics Corporate Logo

Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Jan 07, 2015, 08:30 ET

Relmada Therapeutics to Present at OneMedForum in San Francisco

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today...

Jan 06, 2015, 08:30 ET

Relmada Therapeutics to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Dec 22, 2014, 08:30 ET

Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Dec 18, 2014, 16:35 ET

Relmada Therapeutics Announces Results of Annual Shareholders Meeting

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced the...

Dec 10, 2014, 08:30 ET

Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Dec 03, 2014, 08:00 ET

Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference

Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, is pleased to...

Dec 02, 2014, 08:30 ET

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone

Novel Product Virtually Devoid of Opioid Activity Being Studied in Neuropathic Pain. Relmada Therapeutics, Inc. (OTCQB: RLMD), a...

Nov 24, 2014, 08:30 ET

Relmada Therapeutics To Present At LD MICRO Conference

 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Nov 04, 2014, 08:00 ET

Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development

 Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...

Oct 16, 2014, 08:00 ET

Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants

 Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced...